on Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Protagonist Therapeutics Nominates PN-881 for Immune-Mediated Skin Disorders
Protagonist Therapeutics has announced the nomination of PN-881, a potential best-in-class oral peptide IL-17 antagonist, for development in treating immune-mediated skin diseases. The peptide has shown high potency against three dimeric forms of IL-17 (AA, AF, and FF), with plans for Phase I trials set for Q4 2025 following ongoing IND enabling studies.
PN-881 has demonstrated superior potency compared to existing therapies, including secukinumab, and rivals the efficacy of leading antibody drugs. The nomination marks a significant step in Protagonist's oral peptide development, showcasing the company's commitment to innovative therapeutics for skin diseases.
The company's progress with PN-881 will be discussed in a webcast today at 4:30 pm ET, providing insights into future trials and market potential.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Protagonist Therapeutics, Inc. news